Vitamin D metabolites and risk of first clinical diagnosis of central nervous system demyelination
Low 25-hydroxyvitamin D (25(OH)D) concentration is a recognised risk factor for multiple sclerosis (MS). Associations with vitamin D metabolites and vitamin D binding globulin (VDBG) have not been widely studied. We assessed the association between vitamin D metabolites (25(OH)D2, 25(OH)D3, c3-epime...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Journal Article |
| Language: | English |
| Published: |
PERGAMON-ELSEVIER SCIENCE LTD
2022
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/20.500.11937/90046 |
| _version_ | 1848765318437011456 |
|---|---|
| author | Tiller, C. Black, Lucinda Ponsonby, A.L. Taylor, B. van der Mei, I. Clarke, M.W. Lucas, R.M. |
| author_facet | Tiller, C. Black, Lucinda Ponsonby, A.L. Taylor, B. van der Mei, I. Clarke, M.W. Lucas, R.M. |
| author_sort | Tiller, C. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Low 25-hydroxyvitamin D (25(OH)D) concentration is a recognised risk factor for multiple sclerosis (MS). Associations with vitamin D metabolites and vitamin D binding globulin (VDBG) have not been widely studied. We assessed the association between vitamin D metabolites (25(OH)D2, 25(OH)D3, c3-epimer 25(OH)D3, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), and 24,25-dihydroxyvitamin D3 (24,25(OH)2D3)) measured by liquid chromatography-tandem mass spectrometry assays, VDBG measured using a polyclonal immunoassay, and calculated free and bioavailable 25(OH)D, free 1,25(OH)2D3, and the 24,25(OH)2D3: total 25(OH)D and total 1,25(OH)2D: total 25(OH)D ratios with risk of a first clinical diagnosis of CNS demyelination (FCD) in an Australian case-control study (n = 196 cases, n = 241 controls, matched on age, sex and study region). Higher 25(OH)D (adjusted odds ratio (AOR) = 0.94 (95 % confidence interval (CI) 0.85−1.03) per 10 nmol/L increment) and 24,25(OH)2D3 (AOR = 0.81 (95 %CI 0.65−1.00) per 1 nmol/L increment) concentrations were associated with reduced FCD risk. Our results were compatible with no association for the other vitamin D metabolites, ratios, or VDBG with FCD risk. Thus, using standardised assays, and a comprehensive range of vitamin D metabolites, we confirmed the association of higher 25(OH)D and reduced FCD risk, and describe a similar effect for 24,25(OH)2D3; free or bioavailable 25(OH)D were not associated with FCD risk. |
| first_indexed | 2025-11-14T11:33:21Z |
| format | Journal Article |
| id | curtin-20.500.11937-90046 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| language | English |
| last_indexed | 2025-11-14T11:33:21Z |
| publishDate | 2022 |
| publisher | PERGAMON-ELSEVIER SCIENCE LTD |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-900462023-02-08T04:08:14Z Vitamin D metabolites and risk of first clinical diagnosis of central nervous system demyelination Tiller, C. Black, Lucinda Ponsonby, A.L. Taylor, B. van der Mei, I. Clarke, M.W. Lucas, R.M. Science & Technology Life Sciences & Biomedicine Biochemistry & Molecular Biology Endocrinology & Metabolism Multiple sclerosis Vitamin D Free vitamin D Vitamin D binding protein First demyelinating event D-BINDING PROTEIN MULTIPLE-SCLEROSIS 25-HYDROXYVITAMIN D ENVIRONMENT ADULTS RATIO Low 25-hydroxyvitamin D (25(OH)D) concentration is a recognised risk factor for multiple sclerosis (MS). Associations with vitamin D metabolites and vitamin D binding globulin (VDBG) have not been widely studied. We assessed the association between vitamin D metabolites (25(OH)D2, 25(OH)D3, c3-epimer 25(OH)D3, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), and 24,25-dihydroxyvitamin D3 (24,25(OH)2D3)) measured by liquid chromatography-tandem mass spectrometry assays, VDBG measured using a polyclonal immunoassay, and calculated free and bioavailable 25(OH)D, free 1,25(OH)2D3, and the 24,25(OH)2D3: total 25(OH)D and total 1,25(OH)2D: total 25(OH)D ratios with risk of a first clinical diagnosis of CNS demyelination (FCD) in an Australian case-control study (n = 196 cases, n = 241 controls, matched on age, sex and study region). Higher 25(OH)D (adjusted odds ratio (AOR) = 0.94 (95 % confidence interval (CI) 0.85−1.03) per 10 nmol/L increment) and 24,25(OH)2D3 (AOR = 0.81 (95 %CI 0.65−1.00) per 1 nmol/L increment) concentrations were associated with reduced FCD risk. Our results were compatible with no association for the other vitamin D metabolites, ratios, or VDBG with FCD risk. Thus, using standardised assays, and a comprehensive range of vitamin D metabolites, we confirmed the association of higher 25(OH)D and reduced FCD risk, and describe a similar effect for 24,25(OH)2D3; free or bioavailable 25(OH)D were not associated with FCD risk. 2022 Journal Article http://hdl.handle.net/20.500.11937/90046 10.1016/j.jsbmb.2022.106060 English http://creativecommons.org/licenses/by-nc-nd/4.0/ PERGAMON-ELSEVIER SCIENCE LTD fulltext |
| spellingShingle | Science & Technology Life Sciences & Biomedicine Biochemistry & Molecular Biology Endocrinology & Metabolism Multiple sclerosis Vitamin D Free vitamin D Vitamin D binding protein First demyelinating event D-BINDING PROTEIN MULTIPLE-SCLEROSIS 25-HYDROXYVITAMIN D ENVIRONMENT ADULTS RATIO Tiller, C. Black, Lucinda Ponsonby, A.L. Taylor, B. van der Mei, I. Clarke, M.W. Lucas, R.M. Vitamin D metabolites and risk of first clinical diagnosis of central nervous system demyelination |
| title | Vitamin D metabolites and risk of first clinical diagnosis of central nervous system demyelination |
| title_full | Vitamin D metabolites and risk of first clinical diagnosis of central nervous system demyelination |
| title_fullStr | Vitamin D metabolites and risk of first clinical diagnosis of central nervous system demyelination |
| title_full_unstemmed | Vitamin D metabolites and risk of first clinical diagnosis of central nervous system demyelination |
| title_short | Vitamin D metabolites and risk of first clinical diagnosis of central nervous system demyelination |
| title_sort | vitamin d metabolites and risk of first clinical diagnosis of central nervous system demyelination |
| topic | Science & Technology Life Sciences & Biomedicine Biochemistry & Molecular Biology Endocrinology & Metabolism Multiple sclerosis Vitamin D Free vitamin D Vitamin D binding protein First demyelinating event D-BINDING PROTEIN MULTIPLE-SCLEROSIS 25-HYDROXYVITAMIN D ENVIRONMENT ADULTS RATIO |
| url | http://hdl.handle.net/20.500.11937/90046 |